Skip to Content

Join the 'Evomela' group to help and get support from people like you.

Evomela News

U.S. Pays Highest Prices for Cancer Meds: Study

Posted 6 Jun 2016 by Drugs.com

MONDAY, June 6, 2016 – The United States pays the highest prices in the world for generic and brand-name cancer drugs, a new study has found. However, as the world's wealthiest nation, the United States is better able to pay for those pricey drugs than poorer countries with somewhat lower medication prices, added study lead author Dr. Daniel Goldstein. People in China and India are much less able to afford cancer drugs than Americans, he said, even though U.S. monthly drug prices are about three to six times higher in the United States. That doesn't mean America came out on top in overall drug affordability, however. Developed nations such as Australia, England and Israel had the "best deal" in the world on cancer drugs, thanks to government programs that regulate drug pricing, the study found. "America is the wealthiest nation, but its drug prices are significantly higher – so much ... Read more

Related support groups: Cancer, Provera, Depo-Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Tamoxifen, Medroxyprogesterone, Arimidex, Tretinoin, Fluorouracil, Lupron Depot, Femara, Gleevec, Lung Cancer, Colorectal Cancer, Isotretinoin, Rituxan, Claravis

HIV Patients Less Likely to Get Treatment for Cancer: Study

Posted 17 May 2016 by Drugs.com

TUESDAY, May 17, 2016 – While powerful HIV medications are granting longer lives to many people infected with the virus, a new U.S. study shows these same patients are less likely to get treatment for cancer if it develops. It's not clear why the difference exists. It could reflect the decisions of physicians, patients or both. Whatever the case, the finding confirms that the gap persists even when patients have private insurance or are otherwise healthy, the study authors said. Previous research has suggested that "people with well-controlled HIV infection should be treated similarly to patients without HIV," said study author Dr. Gita Suneja. However, "even looking at cancer patients with private health insurance only, we saw that those with HIV infection were less likely to receive cancer treatment for many common cancer types," said Suneja. She is an assistant professor of ... Read more

Related support groups: Cancer, Methotrexate, HIV Infection, Fluorouracil, Lung Cancer, Xeloda, Hydroxyurea, Mercaptopurine, Hydrea, Carboplatin, Cisplatin, Cytoxan, Temodar, Cyclophosphamide, Dacogen, Bendamustine, Gemzar, Treanda, Oxaliplatin, Capecitabine

Could Talk Therapy Ease Chemo-Related Memory Issues?

Posted 2 May 2016 by Drugs.com

MONDAY, May 2, 2016 – A type of psychotherapy might help cancer survivors deal with the long-term thinking problems some experience after chemotherapy, researchers say. It's estimated that about half of those who undergo chemotherapy for cancer develop what's often called "chemo brain." For instance, they may have trouble following conversations or remembering the steps in a project, according to background notes with the new study. Although usually mild, these changes can affect quality of life, job performance and relationships, said the researchers from the Eastern Maine Medical Center and Lafayette Family Cancer Center in Bangor, Maine. The researchers developed a cognitive-behavioral therapy (CBT) program called Memory and Attention Adaptation Training to help cancer survivors prevent or manage these memory problems. Their study involved 47 breast cancer survivors who underwent ... Read more

Related support groups: Cancer, Methotrexate, Breast Cancer, Prostate Cancer, Fluorouracil, Gleevec, Lung Cancer, Renal Cell Carcinoma, Colorectal Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Metastatic, Brain Tumor, Melanoma, Xeloda, Skin Cancer, Tasigna, Pancreatic Cancer, Ovarian Cancer, Endometrial Cancer, Hydroxyurea

FDA Grants Spectrum Pharmaceuticals Approval of Evomela (melphalan) for Injection

Posted 16 Mar 2016 by Drugs.com

HENDERSON, Nev., March 15, 2016 --(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today that the U.S. Food and Drug Administration (FDA) has granted approval of Evomela for use in two indications: 1) use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation (ASCT) in patients with multiple myeloma (MM), and 2) for the palliative treatment of patients with MM for whom oral therapy is not appropriate. This is the first product to be FDA-approved for the high-dose conditioning indication in MM. “I am very proud to announce that Spectrum has been able to bring another new cancer drug to the market,” said Rajesh C. Shrotriya, MD, Chairman and Chief Executive Officer of Spectrum Pha ... Read more

Related support groups: Multiple Myeloma, Melphalan, Evomela

Ask a Question

Further Information

Related Condition Support Groups

Multiple Myeloma

Evomela Patient Information at Drugs.com